Functional disorders concern both mind and body – a patient’s emotional and psychological state can affect, or create, physical symptoms. These symptoms are absolutely genuine but are not due to an underlying physical abnormality or disease.

Therefore patients may display dramatic symptoms – abdominal pain, bloating, diarrhoea, headaches and chronic fatigue – but these are symptoms related to no identified disease or physical cause. Irritable Bowel Syndrome (IBS) has long been considered a functional disorder due to a perceived impact of social and psychological factors on the somatic disease process. Decades of research has shown that stress can be an aggravating factor for IBS. 

Suzanne O’Sullivan’s book, It’s All In Your Head, examines functional disorders, showing it to be a ‘serious disease of modern society: misunderstood, misdiagnosed and surrounded by fire’. Doctor O’Sullivan, a consultant neurologist of over 10 years, wrote the book to shine a light on functional disorders, illuminating how common they are in a bid to raise awareness and to help patients to understand their symptoms. Fundamentally, her findings were that symptoms stemming from functional disorders must be treated as seriously as issues rooted in physical illness. 

Dr. O’Sullivan states that as a society we must all accept the power of the mind over the body and understand that there is no quick or single solution for this form of illness: “To look for one is akin to looking for the cure of unhappiness. There is no single answer because there is no single cause.” 

For more information about functional disorders or Irritable Bowel Syndrome, please do not hesitate to contact Dr. Harris.

Filgotinib is a Janus kinase 1 (JAK1) inhibitor, that was reported in The Lancet to show positive results in patients with Crohn’s disease. Filgotinib is a “small molecule drug” that is taken by mouth & unlike the existing treatments for Crohn’s disease (biological agents such as infliximab & adalimumab) does not directly affect TNF but inhibits the activity of JAK1 & thereby reduces the inflammation causing Crohn’s disease.

 In the study, 175 patients with moderate-to-severe Crohn’s disease were randomised to receive 200 mg filgotinib or placebo (a similar looking but inactive tablet). Filgotinib induced clinical remission in 48% of the patients, compared with 23% of the patients given placebo. In addition, more patients given filgotinib had an improvement in their quality of life (34%) than those given placebo (18%).

 While there is still much work ahead, this Phase 2 study highlights filgotinib’s potential as an oral treatment for the treatment of Crohn’s disease.

 For more information about this treatment option or Crohn’s disease, please do not hesitate to contact Dr. Harris.

At West Kent Gastroenterology, we work hard to provide our patients with top-class care. You will enjoy friendly, fast and modern treatment by a highly experienced gastroenterologist. We carefully review patient satisfaction and feedback, and at West Kent Gastroenterology we are continuously making improvements to our services, ensuring the highest level of care possible.

Clinic Locations

Nuffield Hospital
Kingswood Road, Tunbridge Wells, TN2 4UL

Spire Hospital
Fordcombe Road, Tunbridge Wells, Kent, TN3 0RD

Sevenoaks Medical Centre
London Road, Sevenoaks, Kent, TN13 2JD


@dradamharris - 1 week

Eosinophilic oesophagits (EoE) is getting more common; the reasons for this are unclear. There is an inverse relati…

@dradamharris - 1 week

Thanks Jonny, Miles's excellent talk is summarised here:

© 2019 West Kent Gastroenterology Ltd.

Designed and Developed By